The chalcone butein from Rhus verniciflua Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts

被引:59
作者
Samoszuk M. [1 ]
Tan J. [1 ]
Chorn G. [2 ]
机构
[1] Pathology Department, University of California, Irvine Medical Center, Orange, CA 92868
[2] Biology Department, Stanford University, Stanford, CA
来源
BMC Complementary and Alternative Medicine | / 5卷 / 1期
关键词
Breast Cancer Cell; Troglitazone; Human Breast Cancer Cell Line; Normal Fibroblast; Clonogenic Growth;
D O I
10.1186/1472-6882-5-5
中图分类号
学科分类号
摘要
Background: Butein (3,4,2′,4′-tetrahydroxychalone), a plant polyphenol, is a major biologically active component of the stems of Rhus verniciflua Stokes. It has long been used as a food additive in Korea and as an herbal medicine throughout Asia. Recently, butein has been shown to suppress the functions of fibroblasts. Because fibroblasts are believed to play an important role in promoting the growth of breast cancer cells, we investigated the ability of butein to inhibit the clonogenic growth of small numbers of breast cancer cells co-cultured with fibroblasts in vitro. Methods: We first measured the clonogenic growth of small numbers of the UACC-812 human breast cancer cell line co-cultured on monolayers of serum-activated, human fibroblasts in the presence of butein (2 μg/mL) or various other modulators of fibroblast function (troglitazone-1 μg/mL; GW9662-1 μM; meloxican-1 μM; and 3,4 dehydroproline-10 μg/mL). In a subsequent experiment, we measured the dose-response effect on the clonogenic growth of UACC-812 breast cancer cells by pre-incubating the fibroblasts with varying concentrations of butein (10 μg/ml-1.25 μg/mL). Finally, we measured the clonogenic growth of primary breast cancer cells obtained from 5 clinical specimens with normal fibroblasts and with fibroblasts that had been pre-treated with a fixed dose of butein (2.5 μg/mL). Results: Of the five modulators of fibroblast function that we tested, butein was by far the most potent inhibitor of clonogenic growth of UACC-812 breast cancer cells co-cultured with fibroblasts. Pre-treatment of fibroblasts with concentrations of butein as low as 2.5 μg/mL nearly abolished subsequent clonogenic growth of UACC-812 breast cancer cells co-cultured with the fibroblasts. A similar dose of butein had no effect on the clonogenic growth of breast cancer cells cultured in the absence of fibroblasts. Significantly, clonogenic growth of the primary breast cancer cells was also significantly reduced or abolished when the tumor cells were co-cultured with fibroblasts that had been pre-treated with a fixed dose of butein. Conclusion: We conclude that fibroblasts pre-treated with non-toxic doses of butein (a natural herbal compound) no longer support the clonogenic growth of small numbers of primary breast cancer cells seeded into co-cultures. These results suggest that interference with the interaction between fibroblasts and breast cancer cells by the natural herbal compound, butein, should be further investigated as a novel experimental approach for possibly suppressing the growth of micrometastases of breast cancer. © 2005 Samoszuk et al; licensee BioMed Central Ltd.
引用
收藏
页数:5
相关论文
共 21 条
[1]  
Kang D.G., Lee A.S., Mun Y.J., Woo W.H., Kim Y.C., Sohn E.J., Moon L.K., Lee H.S., Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats, Biol. Pharm. Bull., 27, pp. 366-370, (2004)
[2]  
Lee J.C., Lee K.Y., Kim J., Na C.S., Jung N.C., Chung G.H., Jang Y.S., Extract from Rhus verniciflua Sokes is capable of inhibiting the growth of human lymphoma cells, Food Chemical Toxicol., 42, pp. 1383-1388, (2004)
[3]  
Lee S.H., Nan J.X., Zhao Y.Z., Woo S.W., Park E.J., Kang T.H., Seo G.S., Kim Y.C., Sohn D.H., The chalcone butein from Rhus verniciflua shows antifibrogenic activity, Planta Med., 69, pp. 990-994, (2003)
[4]  
Woo S.W., Lee S.H., Kang H.C., Park E.J., Zhao Y.Z., Kim Y.C., Sohn D.W., Butein suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture, J. Pharmacy and Pharmacol., 55, pp. 347-352, (2003)
[5]  
Mueller M.M., Fusenig N.E., Friends or foes-bipolar effects of the tumour stroma in cancer, Nature Reviews Cancer, 4, pp. 839-849, (2004)
[6]  
Bhowmick N.A., Neilson E.G., Moses H.L., Stromal fibroblasts in cancer initiation and progression, Nature, 432, pp. 332-337, (2004)
[7]  
Burstein H.J., Demetri G.D., Mueller E., Sarraf P., Spiegelman B.M., Winer E.P., Use of peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer, Breast Cancer Res. Treat., 79, pp. 391-397, (2003)
[8]  
Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiamatsu R., A synthetic agonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation, J. Biol. Chem., 275, pp. 1873-1877, (2000)
[9]  
Seargent J.M., Yates E.A., Gill J.H., GW9662, a potent antagonist of PPAR-gamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR gamma agonist rosiglitazone, independentlh of PPAR gamma activation, Br. J. Pharmacol.
[10]  
Hussey H.J., Tisdale M.J., Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model, Int. J. Cancer, 87, pp. 95-100, (2000)